Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | IMA970A |
Trade Name | |
Synonyms | IMA-970A|IMA 970A |
Drug Descriptions |
IMA970A is a cancer vaccine comprising 16 synthetic tumor-associated peptides (TUMAPs), which potentially induces anti-tumor HLA class I and II T-cell responses (PMID: 35421231). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C151942 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
CV8102 + IMA970A | CV8102 IMA970A | 0 | 0 |
Durvalumab + IMA970A + Montanide ISA 51 | Durvalumab IMA970A Montanide ISA 51 | 0 | 1 |
IMA970A | IMA970A | 0 | 0 |